GRAIL, Inc. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $37.5 million (+3.7% year over year) and diluted EPS of -$2.21. It usually reports 12–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
From press release
|
Q3 FY2026
ended Sep 30, 2026
|
38
+3.7%
|
-104
-16.4%
|
-2.21
+10.2%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
45
+25.7%
|
-110
+3.3%
|
-2.56
+19.5%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
41
+28.1%
|
-93
+12.3%
|
-2.29
+26.1%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
44
+14.0%
|
-99
-2.2%
|
-2.44
+15.7%
|
|
Oct 16, 2025
16 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
36
+26.3%
|
-89
+29.2%
|
-2.46
+37.6%
|
|
Aug 12, 2025
43 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
36
+11.2%
|
-114
+92.8%
|
-3.18
+93.8%
|
|
May 13, 2025
43 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
32
|
-106
|
-3.10
|
|
Jan 15, 2025
15 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
38
|
-97
|
-2.89
|
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- GRAL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Sunnyvale, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1699031
- Former names
- GRAIL, LLC (until Jun 12, 2024)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Source: SEC EDGAR filings. This is company-reported data, not investment advice.